PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Inclisiran - Lipid modification
PAD Profile : Inclisiran - Lipid modification
Keywords :
primary hypercholesterolaemia, mixed dyslipidaemia, lipid-lowering, lipid lowering
Brand Names Include :
Leqvio
Traffic Light Status
Status 1 of 1.
Status :
Green
Important
Formulations :
- Subcutaneous injection (sc)
Important Information :
Prescribing in secondary care is commissioned by NHSE - Blueteq forms are required.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Atorvastatin
- Rosuvastatin calcium
- Simvastatin
- Ezetimibe
- Pravastatin sodium
- Fluvastatin sodium
- Evolocumab
- Alirocumab
- Fenofibrate
- Bezafibrate
- Ciprofibrate
- Gemfibrozil
- Colesevelam hydrochloride
- Colestyramine
- Bempedoic acid
- Icosapent
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
NICE TA733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia - Oct 2021
Committee Recommendations
Date
Committee Name
Narrative
06 October 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
Decision reviewed March 2022
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agree inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia in line with NICE TA733
A GREEN traffic light status will be applied to inclisiran.
Key points:
- It should be a shared decision making process between the patient and the prescribing clinician in line with NICE.
- Patient should be on maximum tolerated lipid-lowering therapy prior to initiation with inclisiran.
- Can be used in combination with statins or other lipid lowering treatments OR
- As monotherapy only if a person was unable to take any other type of lipid-lowering therapy
Associated BNF Codes
02. Cardiovascular System
02.12.00. Lipid-regulating drugs